PTK2 and neoplasm: Inhibition of Rho-kinase and FAK-mediated cell contraction (e.g., Fasudi, H1152, Defactintb)Reduction of matrix components (e.g., FAP gene-editing cells, FAP-vaccine, FAP antibody-nanoparticle, VS-4718, and PEGPH20)Inhibition of matrix cross-linking (e.g., BAPN and miRNA LOX inhibitors) and fibrosis (e.g., pirfenidone, losartan, and tranilast)Improvement of tumor vascular leakage (e.g., bevacizumab)Reduction of the effect of vascular shear stress.